Pharmacoeconomic analysis of a maintenance strategy with lopinavir/ritonavir monotherapy in HIV-infected patients;Análisis farmacoeconómico de una estrategia de mantenimiento con lopinavir/ritonavir como monoterapia en pacientes con infección por el VIH

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 24, Issue 8, 2006, Pages 490-494

  Escobar, Ismael ^a   Pulido, Federico ^a   Pérez, Esther ^b   Arribas, José Ramón ^b   García, María Del Pilar ^a   Hernando, Asunción ^c  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^c UNIVERSIDAD EUROPEA DE MADRID   (Spain)

Author keywords

Cost efficacy; Induction maintenance; Lopinavir ritonavir

Indexed keywords

LOPINAVIR PLUS RITONAVIR; VIRUS RNA;

ADULT; ARTICLE; BLOOD ANALYSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; OPEN STUDY; RANDOMIZED CONTROLLED TRIAL; VIRUS LOAD;

EID: 33750989937     PISSN: 0213005X     EISSN: None     Source Type: Journal    
DOI: 10.1157/13092464     Document Type: Article

References (11)

1. Iribarren JA, Labarga P, Rubio R, Berenguer J, Miró JM, Antela A, et al. Recomendaciones de GESIDA/Plan Nacional sobre el SIDA respecto al tratamiento antirretroviral en pacientes adultes infectados por el virus de la inmunodeficiencia humana (octubre 2004). Enferm Infecc Microbiol Clin. 2004;22:564-642.
2. Hall D, Montaner J, Reiss P, Cooper D, Vella S, Dohnanyi C, et al. Induction-maintenance antiretroviral therapy: proof of concept. AIDS. 1998;12: 41-4.
3. Reijers M, Weverlion G, Jurriaans S, Wit FW, Weigel HM, Tenkate RW, et al. Maintenace therapy after cuadruple induction therapy in HIV-1 infected individuals: Amsterdam Duration of Antiretroviral Medication (ADAM) study. Lancet. 1998;352:185-90.
4. Havlir D, Marschner I, Hirsch M, Collier AC, Tebas P, Bassett RL, et al. Maintenace antiretroviral therapies in HIV-infected subjects with undetectable plasma HIV RNA after triple-drug therapy. N Engl J Med. 1998;339: 1261-8.
5. Pialoux G, Raffi F, Brun-Vezinet F, Meiffredy V, Flandre P, Gastaut JA, et al. A randomized trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously HIV-1 infected patients. N Engl J Med. 1998;339:1269-76.
6. Murphy R, Brun S, Hicks C. ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antirretroviral-naive adults with HIV-1 infection: 48-weeks results. AIDS. 2001;15:1-9.
7. Kempf D, King M, Bernstein B, Cernohous P, Bauer E, Moseley J, et al. Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine. J Infect Dis. 2004;189:51-60.
8. Arribas JR, Pulido F, Delgado R, Lorenzo A, Miralles P, Arranz A, et al. Lopinavir/ritonavir as single-drug therapy for maintenance of HIV-1 viral suppression: 48 weeks results of a randomized, controlled, open label, proof-of concept, pilot clinical trial (OK Study). J Acquir Immune Defic Syndr. 2005; 40:280-7.
9. Freedberg KA, Losina E, Weinstein MC, Paltiel AD, Cohen CJ, Seage GR, et al. The cost effectiveness of combination antiretroviral therapy for HIV disease. N Engl J Med. 2001;344:824-31.
10. Cook J, Dasbach E, Coplan P, Markson L, Yin D, Meihbohm A, et al. Modeling the long-term outcomes and costs of HIV antiretroviral therapy using HIV RNA levels: Application to a clinical trial. AIDS Res and Hum Retrov. 1999;15:499-508.
11. Serrano D, Magaz S, Badia X, Álvarez C, Green J. Análisis coste-efectividad de Fuzeon® + Terapia Optimizada (TO) frente a TO en pacientes infectados de VIH-1/SIDA resisten tes a las terapias antiretrovirales (AVR). XI Congreso de la Socíedad Española de Enfermedades Infecciosas y Microbiología Clínica, Bilbao 2004 (Abstract 463).